Zacks Research Has Optimistic Outlook of REVB Q2 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Research analysts at Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for shares of Revelation Biosciences in a research report issued to clients and investors on Friday, May 8th. Zacks Research analyst B. Sorensen now anticipates that the company will post earnings per share of ($0.88) for the quarter, up from their prior estimate of ($1.46). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($5.24) per share. Zacks Research also issued estimates for Revelation Biosciences’ Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($5.20) EPS and FY2027 earnings at ($2.56) EPS.

Separately, Weiss Ratings raised Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Revelation Biosciences Stock Performance

Shares of NASDAQ:REVB opened at $1.04 on Wednesday. The firm has a 50 day simple moving average of $1.18 and a 200 day simple moving average of $2.52. Revelation Biosciences has a 52 week low of $0.88 and a 52 week high of $39.89. The company has a market cap of $4.07 million, a PE ratio of -0.03 and a beta of -0.14.

Revelation Biosciences (NASDAQ:REVB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($2.71) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($1.56).

Institutional Trading of Revelation Biosciences

Several large investors have recently made changes to their positions in the business. Sabby Management LLC increased its holdings in shares of Revelation Biosciences by 214.7% in the third quarter. Sabby Management LLC now owns 207,051 shares of the company’s stock valued at $294,000 after purchasing an additional 141,262 shares in the last quarter. Armistice Capital LLC bought a new position in Revelation Biosciences in the third quarter valued at about $114,000. Finally, Geode Capital Management LLC acquired a new stake in Revelation Biosciences in the fourth quarter worth about $27,000. Institutional investors own 12.80% of the company’s stock.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.